Bromodichloromethane

CASRN 75-27-4

  • IRIS Summary (PDF) (18 pp, 135 K)
  • Status: Bromodichloromethane is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (18 pp, 135 K) last updated: 09/30/1987

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
2 x10-2 Urinary Renal cytomegaly LOAEL : 1.79 x101
mg/kg-day
1000 Medium

Reference Concentration for Inhalation Exposure (RfC) (PDF) (18 pp, 135 K)
Not assessed under the IRIS Program.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (18 pp, 135 K) last updated: 02/01/1993

WOE Characterization Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Based on inadequate human data and sufficient evidence of carcinogenicity in two animal species (mice and rats) as shown by increased incidence of kidney tumors and tumors of the large intestine in male and female rats, kidney tumors in male mice, and liver tumors in female mice.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (18 pp, 135 K)

Oral Slope Factor: 6.2 x10 -2 per mg/kg-day
Drinking Water Unit Risk: 1.8 x10 -6 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Urinary
Tumor type(s): Kidney (tubular cell adenoma and tubular cell adenocarcinoma) (NTP, 1987)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (18 pp, 135 K)

Not Assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.